Brii expands in infectious via deals with Vir, VBI, WuXi Biologics

Brii Biosciences (Shanghai, China) is broadening its pipeline in HBV and other infectious diseases through a series of new and expanded deals announced Dec. 6, even as CEO Zhi Hong said the company is looking to expand into another therapeutic area.

Brii launched in May with $260 million and three initial partnerships to bring

Read the full 531 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE